Amylyx Pharmaceuticals (AMLX) EBT Margin (2021 - 2024)
Amylyx Pharmaceuticals (AMLX) recorded quarterly EBT Margin of 5684.51% in Q4 2024, up 132.53% quarter-over-quarter from 17476.92% in Q3 2024, and up 567866.0% on a YoY basis from N/an in Q1 2024.
Amylyx Pharmaceuticals (AMLX) EBT Margin (2021 - 2024) Analysis & Trends
Amylyx Pharmaceuticals' EBT Margin history runs 4 years deep, the most recent figure standing at 5684.51% for Q4 2024.
- In Q4 2024, EBT Margin rose 567866.0% year-over-year to 5684.51%; the TTM figure through Sep 2025 stood at 22486.92% (up 2264321.0% YoY), while the FY2024 annual figure was 345.37%, down 35910.0% from the prior year.
- EBT Margin was 5684.51% for Q4 2024 at Amylyx Pharmaceuticals, up from 17476.92% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 5684.51% in Q4 2024 to a low of 17476.92% in Q3 2024.
- Historically, EBT Margin has averaged 3376.89% across 4 years, with a median of 133.74% in 2024.
- The sharpest annual moves came in 2023 and 2024: EBT Margin soared 987210 bps in 2023, then tumbled 1749875 bps in 2024.
- A 4-year view of EBT Margin shows it stood at 8120.0% in 2021, then surged by 98 bps to 194.28% in 2022, then soared by 103 bps to 5.85% in 2023, then soared by 97113 bps to 5684.51% in 2024.
- The last three EBT Margin figures came in at 5684.51% (Q4 2024), 17476.92% (Q3 2024), and 7106.55% (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 10.97% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 33.51% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 40.73% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 25.87% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 30.30% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 6.35% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -156.77% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -16.70% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 41.45% |
| 10 | Amylyx Pharmaceuticals | 1.51 Bn | 1.51 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 5,684.51% |
| Sep 30, 2024 | -17,476.92% |
| Jun 30, 2024 | -7,106.55% |
| Mar 31, 2024 | -133.74% |
| Dec 31, 2023 | 5.85% |
| Sep 30, 2023 | 21.82% |
| Jun 30, 2023 | 22.15% |
| Mar 31, 2023 | 1.66% |
| Dec 31, 2022 | -194.28% |
| Sep 30, 2022 | -9,850.27% |
| Sep 30, 2021 | -8,120.00% |